{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:55:51Z","timestamp":1793660151911,"version":"4.5.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Burosumab, a monoclonal antibody that binds and inhibits FGF23 activity, was approved in 2018 for treatment of children and adults with X-linked hypophosphatemia (XLH), an X-linked dominant disorder due to increased serum fibroblast growth factor 23 (FGF23) concentration. XLH presents with chronic hypophosphatemia that provokes rickets and dental complications in children, which persist in adults accompanied by bone pain, insufficiency fractures, and enthesis calcifications. Historically, treatment relied on oral phosphate and active vitamin D supplementation. Randomized clinical trials have shown that burosumab allows for hypophosphatemia correction and significant improvement of clinical symptoms in both children and adults. Moreover, fracture healing is 16.8 times higher compared with placebo-treated patients. However, optimal treatment duration has not been determined, and there are few data on clinical, biological, or radiological consequences of burosumab discontinuation. We present the case of a 36-year-old young woman with XLH and disability in the context of chronic bilateral femoral shaft fractures progressing despite optimal phosphate and calcitriol supplementation. After only three burosumab doses, fracture lines were no longer visible on X-rays and the patient could stop pain killers. Burosumab was interrupted after 11 months due to lack of insurance reimbursement. Three months after the last injection, a bone scintigraphy performed because of thigh pain recurrence showed healing of previous bilateral femoral fractures and showed the development of a new fracture on the right femoral shaft, in the presence of very high intact FGF23 values (9,330.0 pg\/ml; N 10-50; patient values without treatment: 91.4 pg\/ml). While burosumab may interfere with FGF23 dosage during treatment, it should be nearly totally eliminated after \u226495 days (half-life \u226419 days), suggesting that FGF23 accumulated under burosumab inducing a very rapid relapse of clinical symptoms. Because in some cases burosumab treatment should be interrupted (end of reimbursement, pregnancy in the absence of safety data), further studies are needed to better explain the FGF23 increased levels after burosumab discontinuation and the clinical, biological, and radiological consequences of burosumab withdrawal.<\/jats:p>","DOI":"10.3389\/fendo.2025.1665649","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T04:13:07Z","timestamp":1761192787000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Increased FGF23 and new insufficiency fractures at burosumab discontinuation in X-linked hypophosphatemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Robert","family":"Bandir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Zanisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Nicod-Lalonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gonzalez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00662-x","article-title":"Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia","volume":"18","author":"Trombetti","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa151","article-title":"X-linked hypophosphatemia: A new era in management","volume":"4","author":"Dahir","year":"2020","journal-title":"J Endocr Soc"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2023.101826","article-title":"Burosumab: Current status and future prospects","volume":"38","author":"Goyal","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e002676","DOI":"10.1136\/rmdopen-2022-002676","article-title":"Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment","volume":"9","author":"Kamenicky","year":"2023","journal-title":"RMD Open"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac518","article-title":"Long-term burosumab administration is safe and effective in adults with X-linked hypophosphatemia","volume":"108","author":"Weber","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2024.104958","article-title":"Safety and efficacy of burosumab in improving phosphate metabolism, bone health, and quality of life in adolescents with X-linked hypophosphatemic rickets","volume":"70","author":"Baroncelli","year":"2024","journal-title":"Eur J Med Genet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2024.101819","article-title":"Impact of stopping burosumab treatment at the end of skeletal growth in adolescents with X-linked hypophosphatemia (XLH)","volume":"24","author":"Jarvis","year":"2025","journal-title":"Bone Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72829","article-title":"Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia","volume":"124","author":"Carpenter","year":"2014","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14832","article-title":"The effect of burosumab on intact and C-terminal FGF23 measurements","volume":"99","author":"Ashrafzadeh-Kian","year":"2023","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2020-0460","article-title":"FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference","volume":"58","author":"Piketty","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.570","article-title":"Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia","volume":"56","author":"Zhang","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.611","article-title":"Population pharmacokinetic and pharmacodynamic analyses from a 4-month intradose escalation and its subsequent 12-month dose titration studies for a human monoclonal anti-FGF23 antibody (KRN23) in adults with X-linked hypophosphatemia","volume":"56","author":"Zhang","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/jcph.1950","article-title":"Population pharmacokinetics and pharmacodynamics of burosumab in adult and pediatric patients with X-linked hypophosphatemia","volume":"62","author":"Lee","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ17-0177","article-title":"Definitive surgical treatment of osteomalacia induced by skull base tumor and determination of the half-life of serum fibroblast growth factor 23","volume":"64","author":"Hana","year":"2017","journal-title":"Endocr J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2865","article-title":"Determination of the elimination half-life of fibroblast growth factor-23","volume":"92","author":"Khosravi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0406","article-title":"Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia","volume":"89","author":"Takeuchi","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.6140","article-title":"Pharmacodynamic exposure-response analysis of fracture count data following treatment with burosumab in patients with XLH","volume":"65","author":"Mehta","year":"2025","journal-title":"J Clin Pharmacol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1665649\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T04:13:08Z","timestamp":1761192788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1665649\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":19,"alternative-id":["10.3389\/fendo.2025.1665649"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1665649","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"article-number":"1665649"}}